April 12, 2013
If necessity is indeed the mother of invention, then our current drug development model is ripe for change. "If we want health care and medical products to be accessible, they have to be available at a price that is affordable," says Frank F. Weichold M.D., Ph.D., the Director of Critical Path and Regulatory Science Initiatives at the FDA. "And as such, we have to rethink how we develop drugs, how we develop products, and how we approve them."